Stay updated on Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial
Sign up to get notified when there's something new on the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page.

Latest updates to the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page
- Check6 days agoChange DetectedThe study record now shows recruitment has ended with a note 'No longer looking for participants.' New help sections such as 'How to Read a Study Record', 'Common Questions', and 'How to Join a Study' were added, and the Intervention/Treatment label formatting was updated.SummaryDifference0.6%

- Check13 days agoChange DetectedThe page's revision tag was updated from v3.5.4 to v3.5.5, indicating a small, non-substantive update to the page.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe page's revision label was updated from v3.5.3 to v3.5.4, indicating a backend/template update to the page without changing the displayed study information.SummaryDifference0.1%

- Check48 days agoChange DetectedThe study record was updated to add Janssen Scientific Affairs, LLC as a collaborator and remove the National Cancer Institute (NCI); recent timestamps indicate that the record has been refreshed.SummaryDifference0.3%

- Check56 days agoChange DetectedThe page’s revision/version indicator was updated from v3.5.2 to v3.5.3.SummaryDifference0.1%

- Check63 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

Stay in the know with updates to Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page.